Vaxess Technologies is to receive US Biomedical Advanced Research and Development Authority (BARDA) funding to demonstrate the feasibility of its MIMIX microneedle patch technology for a COVID-19 vaccine, with the aim of designing and developing a scaled manufacturing process for a single-dose, refrigeration-free “combination seasonal protection patch”, incorporating COVID-19 + seasonal influenza protection.
The funding for Vaxess is part of BARDA’s efforts to evaluate innovative vaccination technologies for COVID-19.
The MIMIX patch is shelf stable and can be self-applied, both critical attributes for pandemic response. It uses sustained-release technology to deliver medicines and vaccines through silk microneedles that dissolve at a precise rate in the skin, releasing their treatment at its most effective dose for the most effective length of time.
MIMIX, so named because it achieves a delivery rate for optimal efficacy by mimicking the prolonged exposure period that occurs during a natural infection, is virtually painless and it is removed from the skin a few minutes after application, while the medication continues to be delivered.
Link to Press Release